Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|4|3|255-271

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.4, Iss.3, 2004-03, pp. : 255-271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

By Evangelisti Camilla  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 8, 2013-08 ,pp. : 921-936

Informa Healthcare

Access to resources Recommend Favorite

Bench to Bedside Targeting of FLT3 in Acute Leukemia

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 781-789

Bentham Science Publishers

Access to resources Recommend Favorite

FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications

By  

Current Pharmaceutical Design, Vol. 11, Iss. 26, 2005-10 ,pp. : 3449-3457

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside

By  

Current Medicinal Chemistry, Vol. 14, Iss. 19, 2007-08 ,pp. : 2009-2023

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By Alvarado Yesid   Kantarjian Hagop M.   Luthra Rajyalakshmi   Ravandi Farhad   Borthakur Gautam   Garcia-Manero Guillermo   Konopleva Marina   Estrov Zeev   Andreeff Michael   Cortes Jorge E.  

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

Blackwell Publishing

Access to resources Recommend Favorite